OBJECTIVE: To compare the in vitro sensitivity/resistance to patupilone versus paclitaxel in uterine serous papillary carcinoma (USPC) with high versus low HER-2/neu expression. METHODS: Six primary USPC cell lines, half of which overexpress HER-2/neu at a 3+ level, were evaluated for growth rate and tested for their in vitro sensitivity/resistance to patupilone versus paclitaxel by MTS assays. Quantitative RT-PCR was used to identify potential mechanisms underlying the differential sensitivity/resistance to patupilone versus paclitaxel in primary USPC cell lines. RESULTS: Cell lines overexpressing HER-2/neu showed higher proliferation when compared to low HER-2/neu-expressing cell lines. Compared to low-expressing cell lines, high HER-2/neu expressors were significantly more sensitive to patupilone than to paclitaxel (P<0.0002). In contrast, there was no appreciable difference in sensitivity to patupilone versus paclitaxel in primary USPC cell lines with low HER-2/neu expression. Higher levels of β-tubulin III (TUBB3) and P-glycoprotein (ABCB1) were detected in USPC cell lines with high versus low HER-2/neu expression (P<0.05). CONCLUSIONS: USPC overexpressing HER-2/neu display greater in vitro sensitivity to patupilone and higher levels of the patupilone molecular target TUBB3 when compared to low HER-2/neu expressors. Due to the adverse prognosis associated with HER-2/neu overexpression in USPC patients, patupilone may represent a promising novel drug to combine to platinum compounds in this subset of aggressive endometrial tumors.
OBJECTIVE: To compare the in vitro sensitivity/resistance to patupilone versus paclitaxel in uterine serous papillary carcinoma (USPC) with high versus low HER-2/neu expression. METHODS: Six primary USPC cell lines, half of which overexpress HER-2/neu at a 3+ level, were evaluated for growth rate and tested for their in vitro sensitivity/resistance to patupilone versus paclitaxel by MTS assays. Quantitative RT-PCR was used to identify potential mechanisms underlying the differential sensitivity/resistance to patupilone versus paclitaxel in primary USPC cell lines. RESULTS: Cell lines overexpressing HER-2/neu showed higher proliferation when compared to low HER-2/neu-expressing cell lines. Compared to low-expressing cell lines, high HER-2/neu expressors were significantly more sensitive to patupilone than to paclitaxel (P<0.0002). In contrast, there was no appreciable difference in sensitivity to patupilone versus paclitaxel in primary USPC cell lines with low HER-2/neu expression. Higher levels of β-tubulin III (TUBB3) and P-glycoprotein (ABCB1) were detected in USPC cell lines with high versus low HER-2/neu expression (P<0.05). CONCLUSIONS: USPC overexpressing HER-2/neu display greater in vitro sensitivity to patupilone and higher levels of the patupilone molecular target TUBB3 when compared to low HER-2/neu expressors. Due to the adverse prognosis associated with HER-2/neu overexpression in USPC patients, patupilone may represent a promising novel drug to combine to platinum compounds in this subset of aggressive endometrial tumors.
Authors: F Y Lee; R Borzilleri; C R Fairchild; S H Kim; B H Long; C Reventos-Suarez; G D Vite; W C Rose; R A Kramer Journal: Clin Cancer Res Date: 2001-05 Impact factor: 12.531
Authors: C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne Journal: Cancer Res Date: 1989-04-15 Impact factor: 12.701
Authors: Richard T Penson; Esther Oliva; Steven J Skates; Tina Glyptis; Arlan F Fuller; Annekathryn Goodman; Michael V Seiden Journal: Gynecol Oncol Date: 2004-04 Impact factor: 5.482
Authors: Gini F Fleming; Virginia L Brunetto; David Cella; Katherine Y Look; Gary C Reid; Adnan R Munkarah; Richard Kline; Robert A Burger; Annekathryn Goodman; R Tucker Burks Journal: J Clin Oncol Date: 2004-06-01 Impact factor: 44.544
Authors: K El-Sahwi; S Bellone; E Cocco; M Cargnelutti; F Casagrande; M Bellone; M Abu-Khalaf; N Buza; F A Tavassoli; P Hui; D-A Silasi; M Azodi; P E Schwartz; T J Rutherford; S Pecorelli; A D Santin Journal: Br J Cancer Date: 2009-11-17 Impact factor: 7.640
Authors: Joyce N Barlin; Robert A Soslow; Megan Lutz; Qin C Zhou; Caryn M St Clair; Mario M Leitao; Alexia Iasonos; Martee L Hensley; Richard R Barakat; Xavier Matias-Guiu; Nadeem R Abu-Rustum Journal: Int J Gynecol Cancer Date: 2013-11 Impact factor: 3.437
Authors: Yang Deng; Fan Yang; Emiliano Cocco; Eric Song; Junwei Zhang; Jiajia Cui; Muneeb Mohideen; Stefania Bellone; Alessandro D Santin; W Mark Saltzman Journal: Proc Natl Acad Sci U S A Date: 2016-09-23 Impact factor: 11.205
Authors: Henrica M J Werner; Jone Trovik; Mari K Halle; Elisabeth Wik; Lars A Akslen; Even Birkeland; Therese Bredholt; Ingvild L Tangen; Camilla Krakstad; Helga B Salvesen Journal: PLoS One Date: 2014-02-25 Impact factor: 3.240